Neuroscience Is The Next Oncology: Why Biogen Is Doubling Down

As big names in pharma seem to have been abandoning neuroscience R&D in droves during recent years, Biogen has spotted an opportunity, and is going all in. Tap into the inside track to find out what the “six broad reasons” are for the company entering the neuroscience space in a big way, and discover why Biogen is betting on neuroscience being “the next oncology.” Take a comprehensive look at Biogen’s neuroscience R&D strategy, including their clinical development pipeline, in this illuminating article.